Calithera initiates mid-stage lung cancer study of telaglenastat in immunotherapy combo

Calithera Biosciences (NASDAQ:CALA) has commenced Phase 2 (KEAPSAKE) trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed.

The 120-subject study will evaluate the safety and investigator-assessed progression-free survival of telaglenastat plus this standard-of-care chemoimmunotherapy regimen, as front-line therapy in patients with stage IV non-squamous non-small cell lung cancer, having KEAP1 or NRF2 mutation. Interim data anticipated in 2021.

https://seekingalpha.com/news/3616966-calithera-initiates-mid-stage-lung-cancer-study-telaglenastat-in-combination-of-immunotherapy